0001726495-19-000001.txt : 20190925 0001726495-19-000001.hdr.sgml : 20190925 20190925163210 ACCESSION NUMBER: 0001726495-19-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190925 DATE AS OF CHANGE: 20190925 EFFECTIVENESS DATE: 20190925 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Spotlight Therapeutics, Inc. CENTRAL INDEX KEY: 0001726495 IRS NUMBER: 821864449 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-349629 FILM NUMBER: 191114560 BUSINESS ADDRESS: STREET 1: 1240 HAYES STREET, #7 CITY: SAN FRANCISCO STATE: CA ZIP: 94117 BUSINESS PHONE: 415-634-5170 MAIL ADDRESS: STREET 1: 1240 HAYES STREET, #7 CITY: SAN FRANCISCO STATE: CA ZIP: 94117 D 1 primary_doc.xml X0708 D LIVE 0001726495 Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 (510) 543-0700 DELAWARE None None Corporation true 2017 Mary HaakFrendscho c/o Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 Executive Officer Director President Jacob Corn c/o Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 Director Patrick David Hsu c/o Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 Director Alexander Marson c/o Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 Director Blake Byers c/o Spotlight Therapeutics, Inc. 26118 Research Road Hayward CA CALIFORNIA 94545 Director Other Health Care Decline to Disclose 06b false 2019-09-09 false true false 0 7133331 6899997 233334 Series A-1 Preferred Stock and the underlying Common Stock issuable upon conversion thereof. false 6 0 0 0 false Spotlight Therapeutics, Inc. /s/ Mary HaakFrendscho Mary HaakFrendscho President 2019-09-25